NFE2L2 and cancer: In many types of cancer cells, NRF2 acquires a stable overexpression phenotype, leading to dysregulated cell proliferation and resistance to anti-cancer drugs (Homma et al, 2009), as well as an accelerated evasion to apoptosis (Jiang et al, 2020).